Skip to contentS
Sigyn Therapeutics, Inc.
S
SIGYSigyn Therapeutics, Inc. Q3 2017 · 10-Q
Revenue$255.98K$255.98Kno prior Q3 2016 on file Net Income-$1.50M-$1.50MN/M vs Q3 2016 EPS Diluted-$0.03-$0.03N/M vs Q3 2016 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sigyn Therapeutics, Inc. · CIK 1642159 · Engraved from SEC EDGAR
Operating Cash Flowderived$2,091N/M Free Cash Flowderived$2,091N/M Margins · derivedGross margin61.5%
Operating margin-226.7%
Net margin-585.1%
ended Sep 30, 2017 · filed Nov 13, 2017 · 44 d after period end